SEC Comment Letter 0000000000-23-010057 to SOLIGENIX, INC. (SNGX)
SOLIGENIX, INC.
Date: Sept. 12, 2023 · CIK: 0000812796 · Accession: 0000000000-23-010057
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274265
Letter
United States securities and exchange commission logo September 12, 2023 Christopher Schaber Chief Executive Officer SOLIGENIX, INC. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Re:SOLIGENIX, INC. Registration Statement on Form S-3 Filed August 30, 2023 File No. 333-274265 Dear Christopher Schaber: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Driscoll Ugarte
Show Raw Text
United States securities and exchange commission logo
September 12, 2023
Christopher Schaber
Chief Executive Officer
SOLIGENIX, INC.
29 Emmons Drive, Suite B-10
Princeton, NJ 08540
Re:SOLIGENIX, INC.
Registration Statement on Form S-3
Filed August 30, 2023
File No. 333-274265
Dear Christopher Schaber:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Driscoll Ugarte